Just one note on what I took out of the link I jus
Post# of 56324
Posted On: 10/23/2014 12:37:42 AM
Just one note on what I took out of the link I just provided:
It seems to me the reasons for Bill's overseas trips is based on the information below. If H / C is purposely slowing the License process because demand is being met, then export is the only viable solution to the problem, until recreational is made available. see quote below from the link. GLTA
Quote: We have used a variety of public sources to outline proposed expansion plans by the following 13 LPs and our projections imply that Health Canada has licensed an adequate number of LPs for now and, as mentioned in previous reports, has slowed the granting process to focus on those already licensed. At first the application process was the main focus for Health Canada but we believe the regulator has now switched to focus on inspection and regulation of the LPs. Three of the four public LPs including Bedrocan (TSXV:BED), Organigram (TSXV:OGI) and Tweed (TSXV:TWD) have planned significant production capacity expansions in the next six months; we have approximated those numbers in Figure 3. If the market grows to 45,000 patients that require a combined total of 20,500 kg of MMJ per year, these three LPs alone could be capable of satisfying 70% of the market. Of the remaining nine LPs, eight of them are currently selling and four of those have expansion plans in place before the end of 2014. We acknowledge that these three big public LPs may not operate at full capacity right out of the gate but when combined with the anticipated expansions of other LPs, we believe that supply should be sufficient to stay ahead of demand.
It seems to me the reasons for Bill's overseas trips is based on the information below. If H / C is purposely slowing the License process because demand is being met, then export is the only viable solution to the problem, until recreational is made available. see quote below from the link. GLTA
Quote: We have used a variety of public sources to outline proposed expansion plans by the following 13 LPs and our projections imply that Health Canada has licensed an adequate number of LPs for now and, as mentioned in previous reports, has slowed the granting process to focus on those already licensed. At first the application process was the main focus for Health Canada but we believe the regulator has now switched to focus on inspection and regulation of the LPs. Three of the four public LPs including Bedrocan (TSXV:BED), Organigram (TSXV:OGI) and Tweed (TSXV:TWD) have planned significant production capacity expansions in the next six months; we have approximated those numbers in Figure 3. If the market grows to 45,000 patients that require a combined total of 20,500 kg of MMJ per year, these three LPs alone could be capable of satisfying 70% of the market. Of the remaining nine LPs, eight of them are currently selling and four of those have expansion plans in place before the end of 2014. We acknowledge that these three big public LPs may not operate at full capacity right out of the gate but when combined with the anticipated expansions of other LPs, we believe that supply should be sufficient to stay ahead of demand.
(0)
(0)Creative Edge Nutrition Inc. (FITX) Stock Research Links
In times when you feel low self esteem, disappointment and perhaps even depression.......keep in mind that it may simply be the result of the fact that you are surrounded by ass holes. GLTA